Search Within

Otilia-Liana Dumitrescu

Formats
  1. Meeting Abstract (8)
  2. Journal Article (6)
Groups
  1. Center for Hematologic Malignancies (14)
  2. Department of Medicine (14)
  3. Hematologic Malignancies, Division of (14)
  4. Lymphoma (14)
  5. Radiology, Department of (9)
  6. Body Imaging Service (7)

More Groups

People
  1. Carol Portlock (14)
  2. Andrew Zelenetz (13)
  3. Craig Moskowitz (13)
  4. David Straus (13)
  5. Paul Hamlin (13)
  6. Ariela Noy (8)

More People

Years
  1. 2011 (1)
  2. 2010 (2)
  3. 2009 (3)
  4. 2008 (4)
  5. 2006 (3)
  6. 2005 (1)
Publications
  1. Blood (5)
  2. British Journal of Haematology (3)
  3. Annals of Oncology (2)
  4. Clinical Cancer Research (2)
  5. Journal of Clinical Oncology (1)
  6. Leukemia and Lymphoma (1)
Publishers
  1. American Society of Hematology (5)
  2. John Wiley & Sons (3)
  3. American Association for Cancer Research (2)
  4. Oxford University Press (2)
  5. American Society of Clinical Oncology (1)
  6. Taylor & Francis Group (1)

Results (14)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-hodgkin lymphoma
    Journal Article

    Gerecitano, J.; Portlock, C.; Hamlin, P.; Moskowitz, C. H.; Noy, A.; Straus, D.; Schulman, P.; Dumitrescu, O.; Sarasohn, D.; Pappanicholaou, J.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Final results of a phase II study of sequential R-CHOP and yttrium-90 ibritumomab tiuxetan (RIT) for elderly high risk patients with untreated diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Hamlin, P. A. Jr; Rodriguez, M. A.; Noy, A.; Portlock, C. S.; Straus, D.; McLaughlin, P.; Pro, B.; Fayad, L.; Hagemeister, F.; Wegner, B.; more...
    Blood (2010)

    Fulltext@MSK | Save
  • Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes
    Journal Article

    O'Connor, O. A.; Portlock, C.; Moskowitz, C.; Hamlin, P.; Straus, D.; Gerecitano, J.; Gonen, M.; Dumitrescu, O.; Sarasohn, D.; Butos, J.; more...
    Clinical Cancer Research (2010)

    Fulltext@MSK | Save
  • Rituximab, cyclophosphamide, bortezomib and prednisone (R-CBorP): Final results of a phase I trial evaluating two dosing schedules and the safety of overlapping pegfilgrastim in patients with relapsed/refractory indolent and mantle cell lymphomas
    Meeting Abstract

    Gerecitano, J.; Portlock, C. S.; Hamlin, P. A.; Moskowitz, C. H.; Noy, A.; Straus, D. J.; Schulman, P.; Dumitrescu, O.; Sarasohn, D.; Pappanicholaou, J.; more...
    Blood (2009)

    Fulltext@MSK | Save
  • Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: Results of a multicentre phase 2 clinical trial
    Journal Article

    O'Connor, O. A.; Moskowitz, C.; Portlock, C.; Hamlin, P.; Straus, D.; Dumitrescu, O.; Sarasohn, D.; Gonen, M.; Butos, J.; Neylon, E.; more...
    British Journal of Haematology (2009)

    Fulltext@MSK | Save
  • Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
    Journal Article

    Gerecitano, J.; Portlock, C.; Moskowitz, C.; Hamlin, P.; Straus, D.; Zelenetz, A. D.; Zhang, Z.; Dumitrescu, O.; Sarasohn, D.; Lin, D.; more...
    British Journal of Haematology (2009)

    Fulltext@MSK | Save
  • A phase I study evaluating two dosing schedules of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) in patients with relapsed/refractory indolent and mantle cell lymphomas
    Meeting Abstract

    Gerecitano, J. F.; Portlock, C.; Hamlin, P.; Moskowitz, C.; Noy, A.; Straus, D. J.; Zelenetz, A. D.; Schulman, P.; Dumitrescu, O.; O'Connor, O. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Pralatrexate (PDX) produces a high and durable complete response rate in patients with chemotherapy resistant T-cell lymphomas
    Meeting Abstract

    O'Connor, O. A.; Hamlin, P.; Moskowitz, C.; Portlock, C.; Sarasohn, D.; Dumitrescu, O.; Neylon, E.; Patterson, M.; Zelenetz, A.; Saunders, M.; more...
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • Bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P): Two dosing schedules of a novel phase I regimen in patients with relapsed/refractory indolent and mantle cell lymphomas
    Meeting Abstract

    Gerecitano, J.; Portlock, C.; Hamlin, P.; Moskowitz, C.; Noy, A.; Straus, D.; Zelenetz, A. D.; Schulman, P.; Dumitrescu, O.; O'Connor, O. A.
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma
    Journal Article

    O'Connor, O. A.; Portlock, C.; Moskowitz, C.; Straus, D.; Hamlin, P.; Stubblefield, M.; Dumitrescu, O.; Colevas, A. D.; Grant, B.; Zelenetz, A.
    British Journal of Haematology (2008)

    Fulltext@MSK | Save